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Abstract Non-alcoholic fatty liver disease (NAFLD) is
the most common liver disease in the world and its prev-
alence is rising. In the absence of disease progression, fatty
liver poses minimal risk of detrimental health outcomes.
However, advancement to non-alcoholic steatohepatitis
(NASH) confers a markedly increased likelihood of
developing severe liver pathologies, including fibrosis,
cirrhosis, organ failure, and cancer. Although a substantial
percentage of NAFLD patients develop NASH, the genetic
and molecular mechanisms driving this progression are
poorly understood, making it difficult to predict which
patients will ultimately develop advanced liver disease.
Deficiencies in mechanistic understanding preclude the
identification of beneficial prognostic indicators and the
development of effective therapies. Mouse models of
progressive NAFLD serve as a complementary approach to
the direct analysis of human patients. By providing an
easily manipulated experimental system that can be rigor-
ously controlled, they facilitate an improved understanding
of disease development and progression. In this review, we
discuss genetically- and chemically-induced models of
NAFLD that progress to NASH, fibrosis, and liver cancer
in the context of the major signaling pathways whose
disruption has been implicated as a driving force for their
development. Additionally, an overview of nutritional
models of progressive NAFLD is provided.
Introduction
Approximately one quarter of the global population meets
the criteria for a diagnosis of non-alcoholic fatty liver disease
(NAFLD), making it the most common liver disease in the
world (Lazo and Clark 2008). Characterized by the presence
of hepatic steatosis (fat accumulation in the cells of the liver)
in the absence of excessive alcohol intake, NAFLD is often
referred to as the hepatic manifestation of the metabolic
syndrome (Marchesini et al. 2001). Accordingly, both obese
and diabetic individuals are at particularly high risk, with
estimates of prevalence in these populations as high as
70–90 % (Lazo and Clark 2008; Richard and Lingvay 2011;
Starley et al. 2010). Additional risk factors include ethnicity,
gender, dyslipidemia, and hypertension (Browning et al.
2004; Souza et al. 2012). A trend of steadily increasing
incidence over the last three decades mirrors those of obesity
and type 2 diabetes, demonstrating the growing significance
of NAFLD as a major global health concern.
Though generally asymptomatic, NAFLD often pro-
gresses to more severe conditions, including non-alcoholic
steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer.
Indeed, its rising prevalence is a major factor contributing
to the growing incidence of hepatocellular carcinoma
(HCC) (Rahman et al. 2013; Siegel and Zhu 2009). The
impact of NAFLD as an etiological factor for liver cancer
is projected to expand in coming years as rates of obesity
continue to rise, particularly in children. Since the likeli-
hood of developing more severe liver pathologies is a
function of the length of time an individual is affected,
chronic exposure to a fatty liver environment from a young
age confers an especially high risk of disease progression.
Thus, the current childhood obesity epidemic is expected to
promote an increased incidence of NAFLD-associated liver
cancer in the near future.
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Currently, reliable clinical biomarkers of progressive
NAFLD are not available, and the molecular mechanisms
driving disease advancement in humans remain inade-
quately characterized. As a result, cases are often not rec-
ognized until they reach a stage where attempts at curative
treatment or disease stabilization are largely unsuccessful.
While lifestyle changes such as diet modification and
increased exercise are the primary recommendations for
NAFLD patients, they are of limited benefit to patients
with advanced liver disease. Gaining the ability to more
effectively detect the progression of NAFLD to NASH,
cirrhosis, and HCC is a major focus of ongoing research in
hepatology. Another point of emphasis is the identification
of molecular targets that can be exploited therapeutically to
prevent or reverse disease.
Mouse models provide a powerful system with which to
generate and test hypotheses about the molecular drivers of
NAFLD progression to NASH, fibrosis, cirrhosis, and liver
cancer. They allow a level of experimental control not
possible with human studies, an essential factor in studying
a complex, multifactorial condition such as NAFLD. The
mouse genome has been characterized to a greater extent
than any other animal model, and the resources available to
researchers are unparalleled. The ease with which mouse
colonies can be generated allows experiments to be con-
ducted at sufficient scale to enable mechanistically and
statistically meaningful conclusions. Additionally, the
availability of inbred strains facilitates the design of pre-
cisely controlled experiments in which contributions of
specific genetic elements to a phenotype of interest can be
tested individually through minimization of the confound-
ing effects of a genetically heterogeneous background.
Another important advantage is the ability to control hus-
bandry and environmental conditions, including diet and
the microbiome, which allows standardization of important
variables that can impact liver disease.
Several mouse models with phenotypic characteristics
that closely resemble various aspects of progressive NA-
FLD in humans have been described. While no single
model system completely recapitulates the entire spectrum
of human NAFLD, they collectively provide a wealth of
information on the molecular events that lead to the
development of NASH, fibrosis, cirrhosis, and cancer in the
context of a fatty liver environment. Furthermore, the
ability to study individual phenotypic aspects of the disease
through the use of distinct models can be highly advanta-
geous, facilitating accurate interpretation of results by
providing enhanced control over potentially confounding
variables and allowing comparison across multiple exper-
imental contexts.
In this review, we survey many existing mouse models
of NAFLD, focusing on genetically, chemically, and
nutritionally induced models that progress to inflammation,
fibrosis, and in some cases liver cancer in the absence of
further experimental insult. Distinct models are categorized
based on major signaling pathways whose disruption has
been identified as a driving force for disease development
and progression. Table 1 provides a summary of the
genetic models, their phenotypic characteristics, and their
connection to human liver disease. We recognize that an
abundance of additional mouse models have been descri-
bed that develop progressive NAFLD through the com-
bined effects of multiple etiological factors (e.g.,
transgenic or knockout strains that are sensitized to
chemically- or nutritionally-induced NASH and HCC).
Additionally, several examples have been reported of
genetic modifications or drug treatments that confer pro-
tection in models that otherwise develop progressive NA-
FLD. An important role for the gut microbiota in
influencing disease susceptibility and severity has also
come to be appreciated (Aron-Wisnewsky et al. 2013;
Dapito et al. 2012; Park et al. 2013; Yoshimoto et al. 2013).
While these model systems have provided valuable insight
into the molecular mechanisms of disease development and
progression, they have been reviewed elsewhere (Anstee
and Goldin 2006; Hebbard and George 2011; Nagarajan
et al. 2012; Schattenberg and Galle 2010; Takahashi et al.
2012) and are not discussed here.
Characteristics of progressive NAFLD in humans
Histologically, NAFLD is defined as the presence of
accumulated fat within the cytoplasm of at least 5 % of
hepatocytes (Brunt and Tiniakos 2010). A lipid-specific
stain, such as Oil Red O, can be used to visualize intra-
cellular fat but is not always necessary due to the charac-
teristic appearance of hepatic steatosis in samples prepared
with standard histological techniques [e.g., hematoxylin
and eosin (H&E) staining]. Macrovesicular steatosis is
most commonly observed. Here, one or a few large fat
droplets occupy the majority of a cell’s volume and distort
the nucleus. Microvesicular steatosis is defined as the
cytoplasmic accumulation of several small fat-containing
vesicles that give the cell a foamy appearance without
nuclear displacement. While this condition is more char-
acteristic of acute liver damage (e.g., drug-induced toxic-
ity) rather than chronic injury, it is observed in *10 % of
NAFLD patients (Tandra et al. 2011). Often co-occurring
with macrovesicular steatosis, the presence of microve-
sicular steatosis has been linked to increased disease
severity. For a diagnosis of NASH, hepatocyte injury and
lobular inflammation must be present in addition to stea-
tosis. Injury is usually detected by the presence of enlarged
cells with diffuse cytoplasmic contents and a swollen
appearance, a phenotype referred to as ballooning
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degeneration. This phenomenon is often caused by cyto-
skeletal disruptions, which can be identified by the loss of
keratins 8 and 18, as detected by immunostaining (Lackner
et al. 2008). Dense, eosinophilic structures made up of
compacted cytoskeletal keratins called Mallory–Denk
bodies are also common in cells undergoing ballooning
degeneration.
In addition to histological evidence, liver injury may be
indicated by the presence of elevated levels of liver
enzymes alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) in the blood. However, liver
enzymes are not always increased in NASH, and they may
be increased in its absence. Therefore, histological analysis
must be performed to establish a definitive diagnosis of
NASH (Mofrad et al. 2003; Sorrentino et al. 2004).
Inflammatory infiltration, which can be observed on an
H&E stained section, is mostly lymphocytic. The presence
of hepatic fibrosis is not required for a NASH diagnosis,
but the two conditions frequently occur together. Charac-
terized by the accumulation of excess extracellular matrix
(ECM) and decreased cellularity, liver fibrosis results from
a decline in normal matrix turnover and an increase in
matrix deposition by activated hepatic stellate cells. It can
be detected by histological procedures that distinctly stain
Table 1 Genetic models of progressive NAFLD in mice
Gene/Model Modification NASH Fibrosis Liver
tumors
Observations in human liver disease
PI3K/AKT signaling
Pik3ca Liver-specific transgenic overexpression
of activated mutant
No No Yes Transgenic allele modeled after mutation
detected in HCC
Pten Liver-specific knockout Yes Yes Yes Decreased expression in NAFLD; Loss of
function common in HCC
Akt Liver overexpression via adenoviral or
hydrodynamic injection
Yes No Yes Increased expression in HCC associated with
upregulation of lipogenic genes
JAK/STAT signaling
IL-6 Constitutive knockout Yes No No aIncreased expression in obesity and type 2
diabetes
Il6st Constitutive knockout Yes Yes No aActivating mutations detected in liver cancer
Jak2 Liver-specific knockout Yes Yes No Sequence variants associated with metabolic
syndrome risk
Stat5 Liver-specific knockout No No Yes Pathway activation associated with cirrhosis
risk in NAFLD
PPAR signaling
Acox1 Constitutive knockout Yes Yes Yes Sequence variants in PPAR associated with
NAFLD
Lgals3 Constitutive knockout Yes Yes Yes Sequence variants in PPAR associated with
NAFLD
NF-jB signaling
NEMO Liver-specific knockout Yes Yes Yes Decreased expression in HCC
Atg5 Systemic mosaic deletion Yes No Yes Autophagy is decreased in NAFLD and HCC
Atg7 Liver-specific knockout Yes No Yes Autophagy is decreased in NAFLD and HCC
Becn1 Systemic heterozygosity Yes No Yes Autophagy is decreased in NAFLD and HCC
Polygenic
FLS strain Selective breeding Yes Yes Yes
TSOD strain Selective breeding Yes Yes Yes
SAM metabolism
Mat1a Constitutive knockout Yes No Yes Hypermethylation and decreased expression
in NAFLD, cirrhosis, and HCC
Bhmt Constitutive knockout Yes No Yes Decreased expression and loss-of-function
mutation in HCC
Gnmt Constitutive knockout No Yes Yes Hypermethylation and decreased expression
in NAFLD, cirrhosis, and HCC
NAFLD non-alcoholic fatty liver disease, NASH non-alcoholic steatohepatitis, HCC hepatocellular carcinoma
a Observation in humans is discordant with mouse model
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collagen, the primary component of ECM. Commonly used
techniques include Masson’s trichrome and Sirius Red
staining. Additionally, the extent of stellate cell activation
can be assessed by immunostaining for alpha-smooth
muscle actin (a-SMA) (Feldstein et al. 2005). In some
patients, fibrosis increases in severity to the point of cir-
rhosis, which is characterized by a loss of hepatic structural
architecture, portal hypertension, and the formation of
regenerative nodules.
An estimated 20 % of NAFLD cases advance to NASH
(Attar and Van Thiel 2013), although the precise incidence
of progression is difficult to determine because many cases
are not recognized until advanced disease has already set
in. This point is illustrated by the results of a study
examining suspected NAFLD patients by biopsy, which is
the gold standard for NASH diagnosis. Over half of those
surveyed had definite NASH (Vuppalanchi et al. 2009).
Approximately 15–25 % of NASH cases progress to liver
cirrhosis, which is generally irreversible and represents a
major risk factor for organ failure and HCC (Farrell and
Larter 2006). In fact, the annual risk of HCC development
in patients with cirrhotic NASH has been estimated at
2.6 % (Ascha et al. 2010).
Mouse models of progressive NAFLD
PI3K/AKT signaling
Dynamic regulation of the phosphatidylinositol 3-kinase/
AKT thymoma viral proto-oncogene (PI3K/AKT) signal-
ing pathway is central to a multitude of cellular processes.
Of particular relevance to NAFLD development and pro-
gression is the pathway’s involvement in regulating glu-
cose metabolism as well as cellular proliferation and
survival. Mouse models of progressive NAFLD have been
generated through genetic manipulation of specific factors
involved at different points in the PI3K/AKT pathway,
providing strong evidence for a causal link between per-
turbation of this signaling axis and disease development.
Near the top of the signaling cascade, the catalytic alpha
subunit of PI3K (Pik3ca) relays activation signals from
transmembrane receptor complexes by phosphorylating
target lipid molecules to produce active secondary mes-
sengers. Transgenic mice with liver-specific overexpres-
sion of a mutant version of Pik3ca develop noticeably fatty
livers by 4 weeks of age (Kudo et al. 2011). The transgene
was designed to mimic a recurrent mutation detected in
human HCC (Lee et al. 2005). In this model, severe hepatic
steatosis accompanied by elevated serum ALT occurs by
6 months, and nearly all of the transgenic mice go on to
develop liver tumors within 1 year. Consistent with these
results, mice with liver-specific knockout of Pik3ca are
protected from developing hepatic steatosis when fed a
high fat diet (Chattopadhyay et al. 2011). In this study,
deletion of an alternative PI3K catalytic subunit (Pik3cb)
was found to have no significant effect on lipid accumu-
lation within the liver, demonstrating a specific involve-
ment of Pik3ca in this process. Manipulation of Pik3ca
expression in either direction was associated with coordi-
nate regulation of genes involved in lipogenesis (Chatto-
padhyay et al. 2011; Kudo et al. 2011), implicating fatty
acid synthesis as a contributor to the observed phenotype.
Induction of liver tumorigenesis by overexpression of
mutant Pik3ca occurs in the absence of excessive weight
gain, inflammation, or fibrosis (Kudo et al. 2011). Though
unlike typical human progressive NAFLD in this regard,
the model demonstrates that a steatotic liver can undergo
neoplastic transformation without prior development of
NASH or fibrosis. Models such as this may prove partic-
ularly useful for studying the subset of NAFLD-associated
liver cancer in humans that arises in the absence of cir-
rhosis (Ertle et al. 2011).
Serving as an antagonist to the actions of PI3K, phospha-
tase and tensin homolog (Pten) dephosphorylates activated
phosphatidylinositol secondary messengers to decrease out-
put from the PI3K/AKT signaling pathway. Hepatic Pten
deficiency promotes early-onset steatosis that increases in
severity with age (Horie et al. 2004; Stiles et al. 2004). By
10 weeks, mice develop primarily microvesicular steatosis
without other histological abnormalities and have normal
levels of serum liver enzymes. In contrast to what is
observed upon activation of Pik3ca, this model progresses
to a NASH-like stage characterized by inflammation and
fibrosis before eventually developing liver tumors. At
40 weeks, a mixed micro- and macrovesicular steatosis
phenotype is present, along with Mallory–Denk bodies,
ballooning degeneration, and elevated serum liver enzymes
(Horie et al. 2004). Histologically, disease progression
closely recapitulates the course of human NAFLD. Unlike
the majority of human cases, however, mice exhibit
decreased rather than increased extrahepatic adiposity
(Stiles et al. 2004). The appearance of fatty liver is
attributed primarily to activation of de novo lipogenesis, as
suggested by significantly increased expression of genes
involved in fatty acid synthesis (Horie et al. 2004) and
directly demonstrated by quantitative experiments in which
newly synthesized fatty acids were isotopically labeled
in vivo (Stiles et al. 2004). In addition to functioning as an
endoplasmic reticulum (ER) chaperone, heat shock protein
5 [Hspa5, also called glucose-regulated protein 78 and
binding immunoglobulin protein (GRP78/BiP)] plays a
regulatory role in the PI3K/AKT signaling pathway (Ni
et al. 2011). Liver-specific co-deletion of Pten and Hspa5
accelerates all aspects of disease progression (Chen et al.
2013b). Intriguingly, while NASH development in this
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model is associated with decreased Hspa5 expression,
tumors arise from the proliferation of Hspa5-positive cells
that have escaped Cre-mediated deletion. The authors
suggest that loss of expression initially exacerbates stea-
tosis and liver injury but that maintenance of expression
provides cells with a selective advantage in the damaged
liver environment, allowing them to avoid apoptosis and
proliferate to form tumors. Pten is known to play a critical
role as a tumor suppressor molecule. Targeted disruption of
its function promotes tumorigenesis in a variety of tissues
in mouse models, and it is one of the most frequently
mutated genes in human cancer, including HCC (Hollander
et al. 2011). Downregulation of PTEN has also been
observed in hepatic steatosis in humans (Vinciguerra et al.
2008). Through liver-specific inactivation of Pten in mice,
a direct role for this gene in regulating hepatic triglyceride
dynamics was discovered.
Akt, also known as protein kinase B (PKB), is a serine–
threonine protein kinase that acts as the primary effector
molecule downstream of PI3K. Hepatic overexpression of
activated Akt from an injected adenoviral expression con-
struct resulted in significant fatty liver development in mice
within 4 days (Ono et al. 2003). Though this study did not
assess long-term effects on liver pathology, subsequent
studies utilizing stably integrating transposon vectors
delivered via hydrodynamic tail vein injection revealed that
chronic overexpression of activated Akt causes mice to
develop liver tumors in the context of hepatic steatosis.
When delivered alone, activated Akt was sufficient to
induce mixed micro- and macrovesicular steatosis and
ballooning degeneration within 12 weeks that progressed
to hepatocarcinogenesis within 28 weeks (Calvisi et al.
2011). Tumor formation could be accelerated through co-
delivery of either b-catenin (Stauffer et al. 2011) or Nras
(Ho et al. 2012). As has been observed in human HCC
samples with aberrant activation of AKT (Calvisi et al.
2011), the development of severe hepatic steatosis was
accompanied by enhanced expression of factors involved
in lipogenesis in each of the hydrodynamic delivery mod-
els. Just one of these studies assessed inflammation and
fibrosis, finding only the former to be present (Stauffer
et al. 2011).
Whether through the direct overexpression of activated
Pik3ca or Akt, or as a result of a loss of negative regulation
by Pten, these murine models consistently demonstrate that
hepatic activation of the PI3K/AKT signaling pathway
promotes NAFLD development and progression to liver
cancer.
JAK/STAT signaling
The Janus kinase/signal transducer and activator of tran-
scription (JAK/STAT) signaling cascade is another central
pathway whose regulation is important for a variety of
biological processes and whose disruption can cause pro-
gressive NAFLD. As a major mediator of cytokine sig-
naling, functions of this pathway in the liver include
response to injury and control of inflammation. Multiple
mouse models of progressive NAFLD have been generated
through targeted disruption of normal JAK/STAT signaling
in the liver.
Interleukin-6 (IL-6) is among the many cytokines that
activate JAK/STAT signaling. Constitutive knockout of
this gene causes mice to develop obesity and NASH
(Matthews et al. 2010), which is driven in part by aberrant
metabolic functions within hepatic mitochondria. Global
deletion of IL-6 signal transducer (Il6st; also called gp130)
produces a similar liver phenotype, characterized by stea-
tosis, inflammation, and fibrosis (Betz et al. 1998).
Although sensitized to inflammatory liver injury, mice with
hepatocyte-specific Il6st knockout do not develop liver
pathologies under basal conditions (Streetz et al. 2003),
suggesting that loss of expression in other cell types con-
tributes to the phenotype in constitutive knockout mice.
Given that IL-6 levels are typically increased in NAFLD-
associated conditions such as obesity and type 2 diabetes
(Goyal et al. 2012; Roytblat et al. 2000) and that activating
mutations in IL6ST have been recurrently detected in
human liver cancer (Rebouissou et al. 2009), these results
seem somewhat counterintuitive. Additionally, enhanced
production of IL-6 has been demonstrated to functionally
contribute to chemically-induced hepatocarcinogenesis in
mice (Naugler et al. 2007). The precise role of this cytokine
in metabolic liver disease is therefore controversial (Ouchi
et al. 2011). Whether it promotes or protects from disease
seems to vary depending on contextual factors, including
cell type specific effects, acute versus chronic activation,
and coordination of signals from additional cytokines.
Jak2 is a non-receptor protein tyrosine kinase that
transduces signals from activated membrane receptor pro-
teins to STAT molecules, which subsequently modulate
transcription. Deletion of Jak2 function in a liver-specific
manner causes mice to develop fatty liver by 4 weeks of
age (Sos et al. 2011). Steatosis is initially macrovesicular,
but becomes a mix of micro- and macrovesicular as it
grows progressively worse with age. By 8 weeks the liver
triglyceride content in conditional Jak2 knockout mice is
twenty times higher than that of control mice. NASH and
fibrosis set in by 20 weeks, coincident with the appearance
of elevated serum ALT and AST. Interestingly, these mice
have a significantly lower extra-hepatic fat content than
controls, suggesting a possible role for tissue redistribution
of triglycerides in producing the steatotic phenotype.
Consistent with this hypothesis, the Cd36 fatty acid trans-
port protein was found to be significantly upregulated in
liver. The authors went on to demonstrate that the effects of
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Jak2 deletion on the liver could be prevented by elimi-
nating global growth hormone (GH) signaling (a major
activator of Jak2). They proposed a model wherein the
absence of hepatic Jak2, by failing to propagate GH sig-
nals, causes a loss of feedback inhibition and leads to
increased GH secretion by the pituitary. According to the
model, this increased GH signal promotes lipolysis in
adipose tissue, and the liberated fatty acids are transported
into the liver for storage. Using the same model system,
another group reported a similar steatotic phenotype, but
without progression to inflammation and fibrosis (Shi et al.
2012). This study found hepatic Jak2 deletion to be pro-
tective against high fat diet-induced liver inflammation.
The authors attributed the disparate phenotypes to differ-
ences in genetic background. An association has recently
been reported between polymorphisms in the sequence of
JAK2 and characteristics of the metabolic syndrome in
humans (Penas-Steinhardt et al. 2011), supporting the rel-
evance of these mouse models to human NAFLD.
STAT proteins function as dimeric transcription factors,
translocating from the cytoplasm to the nucleus to regulate
gene expression in response to JAK activation. Liver-spe-
cific deletion of Stat5a and Stat5b (Stat5) was found to cause
NAFLD in mice (Cui et al. 2007). As is observed with
hepatic Jak2 deletion, mice have elevated levels of circu-
lating GH, though a direct contribution to the phenotype was
not investigated. Further characterization showed that mice
develop liver tumors when aged to 17 months, possibly due
to an impaired ability to respond to hepatic injury (Yu et al.
2012). Loss of liver Stat5 expression also sensitizes mice to
chemically-induced hepatic fibrosis (Hosui et al. 2009).
Interestingly, human genome-wide association study
(GWAS) data has identified the STAT5 signaling pathway
as a potential modulator of cirrhosis risk in NAFLD patients
(Chen et al. 2013a). Co-deletion of Stat5 and glucocorticoid
receptor [also called nuclear receptor subfamily 3, group C,
member 1 (Nr3c1)], a co-factor for a subset of Stat5 target
genes, in hepatocytes produces liver tumors with decreased
latency (Mueller et al. 2011). Mice develop combined
micro- and macrovesicular steatosis associated with upreg-
ulated expression of lipogenic factors and increased serum
ALT levels. Consistent with the model proposed by Sos and
colleagues (Sos et al. 2011), elevated levels of circulating
GH promote lipolysis in adipose tissue and hepatic uptake of
fatty acids, which is associated with increased expression of
Cd36. In each of the Stat5 knockout models, expression of
Stat3 is increased. This effect has been mechanistically
implicated in the development of liver disease upon deletion
of Stat5 (Hosui et al. 2009), demonstrating that the role of
JAK/STAT signaling in progressive NAFLD involves a
regulatory function that is more complex than simple gain or
loss of function of the entire pathway.
PPAR signaling
The peroxisome proliferator-activated receptor (PPAR)
family of proteins consists of three nuclear hormone recep-
tors that are important regulators of several NAFLD-related
processes, including the synthesis, transport, and degradation
of lipid molecules. Fatty acids and their metabolic derivatives
act as ligands for PPARs, which upon binding heterodimerize
with retinoid x receptors (RXRs) to form active transcrip-
tional regulator complexes. With regard to fatty acid
metabolism in the liver, PPAR-a and PPAR-b/d mainly
regulate catabolic functions, while PPAR-c is primarily
involved in anabolic functions (Yessoufou and Wahli 2010).
Given their importance in hepatic lipid dynamics, it is not
surprising that several variant PPAR sequences have been
associated with NAFLD in humans (Tailleux et al. 2012).
Additionally, genetically engineered mouse models have
directly demonstrated a key role for aberrant signaling from
this pathway in the development of progressive NAFLD.
Fatty acyl-CoA oxidase 1 (Acox1) is the rate-limiting
enzyme that catalyzes the first step of peroxisomal fatty
acid b-oxidation. Global deletion of this enzyme produces
mice with microvesicular steatosis that develops within
2 months, progresses to steatohepatitis within 5 months,
and is characterized by lymphocytic infiltration and hepa-
tocyte death (Fan et al. 1996). Given the systemic nature of
the model, the degree to which Acox1 deletion in cell types
other than hepatocytes contributes to the liver phenotype is
unclear. Subsequent aging studies found that Acox1-null
mice go on to develop liver fibrosis and HCC (Fan et al.
1998; Huang et al. 2011). The authors suggest that in the
absence of Acox1, accumulation of fatty acid ligands
causes hyperactivation of PPAR-a and that this increased
output promotes hepatocarcinogenesis through excessive
induction of oxidative and endoplasmic reticulum (ER)
stress (Huang et al. 2011; Meyer et al. 2003). The necessity
of PPAR-a for induction of the liver phenotype in Acox1-
null mice is demonstrated by the finding that double
knockout mice do not develop spontaneous steatohepatitis
(Hashimoto et al. 1999). Further support for the conclusion
that overactive PPAR-a signaling contributes to progres-
sive NAFLD comes from the finding that synthetic xeno-
biotic activators of PPAR-a induce fatty liver and HCC
with characteristics similar to various genetic models
(Meyer et al. 2003; Reddy et al. 1980). Additionally,
exposure to trichloroethylene (TCE) or perchloroethylene
(PCE) causes steatohepatitis in mice, an effect attributed to
the metabolic processing of these toxins to PPAR-a ligands
(Wahlang et al. 2013).
Whereas PPAR-a is primarily involved in the break-
down of fatty acids, PPAR-c signaling promotes their
synthesis. This lipogenic activity of PPAR-c has been
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implicated in hepatic steatosis development in mice
through direct overexpression (Yu et al. 2003). Addition-
ally, global knockout of galectin-3 (Lgals3), a member of
the lectin family with a role in inflammation (Henderson
and Sethi 2009), produces a fatty liver phenotype associ-
ated with PPAR-c activation that progresses to fibrotic
NASH and HCC (Nakanishi et al. 2008; Nomoto et al.
2006). As with the Acox1-null mice, this model’s systemic
nature precludes the assignment of functional effects to
specific cell types. Upregulation of PPAR-c has also been
mechanistically linked to steatohepatitis in models gener-
ated through genetic disruption of the PI3K/AKT (Horie
et al. 2004; Kudo et al. 2011) and JAK/STAT (Mueller
et al. 2011; Sos et al. 2011) signaling pathways, indicating
the broad importance of this molecule in the pathogenesis
of progressive NAFLD.
NF-jB signaling
The nuclear factor-kappaB (NF-jB) pathway mediates
several diverse biological processes. These include immune
function, stress response, cell survival, and inflammatory
signaling. In mammals, five NF-jB family member proteins
interact to form dimeric complexes that act as transcription
factors. These complexes translate signals from upstream
molecules in the pathway [including interleukin-1beta (IL-
1b), tumor necrosis factor alpha (TNF-a), and toll-like
receptors (TLRs)] into a modified expression pattern for
distinct sets of target genes. Progressive NAFLD can be
induced in mice through genetic manipulation of indepen-
dent regulatory molecules affecting NF-jB-mediated tran-
scription, demonstrating involvement of this signaling
pathway in disease development.
Carbon tetrachloride (CCl4) is a hepatotoxic agent that is
commonly used to induce steatosis, inflammation, fibrosis,
and liver cancer in mice. In addition to elevated serum
ALT and AST levels, treated mice develop mixed micro-
and macrovesicular steatosis, ballooning degeneration,
Mallory–Denk bodies, and increased collagen deposition
associated with hepatic stellate cell activation (Domitrovic
et al. 2009). CCl4’s mechanism of action is complex and
multifactorial, but is known to involve induction of oxi-
dative stress and disruption of lipid metabolism (Weber
et al. 2003). At the molecular level, activation of the NF-
jB pathway via TNF-a signaling has been shown to be an
important mediator of CCl4’s liver toxicity. Inhibition of
either molecule’s function significantly decreases damage
induced by this agent (Czaja et al. 1995; Wang et al. 1998).
Under basal conditions, NF-jB complexes are seques-
tered in the cytoplasm by inhibitor of jB (IjB) family
proteins. Stimulatory input leads to their degradation,
allowing NF-jB to enter the nucleus and alter transcription.
This process results from phosphorylation of IjB by
complexes of IjB kinase (IKK) and NF-jB essential
modulator (NEMO) proteins, which leads to subsequent
ubiquitination and proteasomal degradation. Liver-specific
ablation of NEMO promotes highly penetrant HCC that is
preceded by steatosis, NASH, and fibrosis (Luedde et al.
2007). In this model, the prevention of hepatic NF-jB
activation causes many cells to undergo apoptosis, and
compensatory proliferation of surviving cells generates a
fatty liver that transitions to inflammatory fibrosis and
HCC. Antioxidant treatment was found to eliminate this
effect, demonstrating its dependence on oxidative stress.
Loss of NEMO protein expression in HCC relative to
adjacent tumor-free liver has been reported in humans
(Aigelsreiter et al. 2012), further supporting a role as a
suppressor of hepatocarcinogenesis.
Autophagy is an important cellular process that mediates
degradation and recycling of intracellular components.
Elimination of its function in the liver through the deletion
of either autophagy-related 5 (Atg5) or autophagy-related
7 (Atg7) causes mice to develop microvesicular steatosis
with modest lymphocytic infiltration and multiple liver
tumors (Singh et al. 2009; Takamura et al. 2011). Simi-
larly, loss of a single beclin 1 (Becn1) allele leads to NASH
and HCC development (Mathew et al. 2009). These phe-
notypes arise, at least in part, as a result of impaired NF-jB
activation in the autophagy-deficient liver. As with the
NEMO knockout mice (Luedde et al. 2007), oxidative
stress is thought to play a driving role in the liver patho-
genesis of these models. This conclusion is consistent with
data from human studies linking decreased autophagy to
NAFLD and HCC (An et al. 2011; Fukuo et al. 2013;
Mathew et al. 2009).
Activation of NF-jB signaling is an important compo-
nent of NAFLD development in the context of hepatic ER
stress (Gentile et al. 2011). Pharmacological ER stress
induced by tunicamycin causes NASH in mice through a
mechanism involving phosphorylation of IjB (Lee et al.
2012). Similarly, induction of ER stress by inhalation of
airborne particulate matter derived from traffic pollution
was found to promote NASH in mice via a mechanism
involving TLR signaling and IjB phosphorylation (Laing
et al. 2010; Zheng et al. 2013).
Polygenic models
The targeted manipulation of individual genes to generate
mouse models of progressive NAFLD is a powerful tech-
nique with several advantages, such as tight control over
experimental variables, high reproducibility, and confident
interpretation of results. A disadvantage of this approach is
that it fails to recreate the complex etiology behind most
cases of human disease. Rather than developing because of
a dysfunctional inherited gene, human NAFLD is generally
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thought to result from the coordinate effects of several
distinct molecules and pathways, along with contributions
from environmental factors. In this regard, polygenic
models more faithfully recapitulate the course of disease
development. It is important to note that the genetic vari-
ants in these models are present ubiquitously and that
atypical function in cell types other than hepatocytes may
be involved in the liver phenotypes developed by these
strains.
The fatty liver Shionogi (FLS) inbred mouse strain was
derived from the Japanese ddN strain through repeated
sibling mating of an outbred colony (Soga et al. 1999).
These mice spontaneously develop microvesicular steatosis
on a normal diet without becoming obese. NAFLD pro-
gresses to chronic NASH, which is associated with bal-
looning degeneration of hepatocytes, inflammatory
infiltration, and fibrosis (Semba et al. 2013). FLS mice
develop HCC with a latency of 16–24 months (Soga et al.
2003). Males are significantly more susceptible to liver
disease than females, mirroring the trend in humans (Ferlay
et al. 2010). Multiple molecular pathways related to fatty
acid metabolism have been implicated as contributors to
the liver phenotype in this strain. Chemical activation of
PPAR-a decreases the severity of steatosis by activating a
set of genes involved in fatty acid catabolism, including
Acox1 (Harano et al. 2006). Along with the studies
showing that hyperactivation of PPAR-a causes NASH
(Fan et al. 1998; Huang et al. 2011; Meyer et al. 2003), this
finding illustrates the dual role that PPAR-a activity may
have as either a protective or promoting factor in pro-
gressive NAFLD depending on the context. Enhanced lipid
transport function resulting from activation of microsomal
triglyceride transfer protein (Mttp) also improves outcome
in FLS mice by alleviating NASH symptoms (Shindo et al.
2010; Wang et al. 2014). Treatment with a non-steroidal
anti-inflammatory drug (NSAID) protects from progression
to HCC without affecting steatosis (Liu et al. 2006),
revealing a key role for inflammatory signaling in driving
hepatocarcinogenesis in this model.
Another polygenic mouse model of spontaneous pro-
gressive NAFLD is the Tsumura Suzuki obese diabetes
(TSOD) strain. Similar to the FLS strain, these mice were
generated through selective inbreeding of a Japanese out-
bred colony of ddY mice (Suzuki et al. 1999). Microve-
sicular steatosis develops in TSOD males by 4 months of
age, and a mixed micro- and macrovesicular steatosis
phenotype with ballooning degeneration and Mallory–
Denk bodies is present at 6 months. By 1 year of age,
livers display inflammatory infiltration, fibrosis, and tumor
development (Nishida et al. 2013). Elevated hepatic levels
of PPAR-c were noted in this model, suggesting that
excessive lipogenesis could be a factor contributing to fatty
liver. It has also been suggested that impaired lipolysis
plays a role in the phenotype of TSOD mice (Yogosawa
et al. 2013).
Nutritional models
One of the most commonly used methods to induce pro-
gressive NAFLD in laboratory mice is through dietary
modification. Many variant diets have been used for this
purpose. Key factors influencing the extent to which each
diet promotes NAFLD, NASH, and HCC include the types
and amounts of fat, carbohydrate, and cholesterol, as well
as the presence or absence of critical nutrients, gender,
strain background, and composition of the gut microbiome.
Interactions between each of these factors ultimately
determine the phenotypic outcome of feeding a modified
diet. Given that dietary factors play a large role in human
NAFLD, these models provide a relevant system in which
to generate and test hypotheses about disease induction and
progression.
Dietary formulations with the majority of calories
derived from fats (typically 30–60 %) are referred to as
high fat diets (HFDs). The increased fat content relative to
a standard laboratory diet can trigger several symptoms of
the metabolic syndrome, including obesity, hyperinsuline-
mia, hypercholesterolemia, and dyslipidemia (Buettner
et al. 2007; Collins et al. 2004). HFDs directly provide an
excess supply of fatty acids to the liver, where their storage
generates conditions of steatosis. Continued exposure to an
HFD can promote inflammation, fibrosis, and HCC (Hill-
Baskin et al. 2009). Diets with increased cholesterol levels
[e.g., the ‘‘Western diet’’ (TD.88137)] are also frequently
used in studies of progressive NAFLD and can affect the
liver phenotype (Matsuzawa et al. 2007).
In addition to its quantity, the source of dietary fat can
significantly impact experimental outcomes. Because of
their different compositions of polyunsaturated (PUFA),
monounsaturated (MUFA), saturated (SFA), and trans-
fatty acid (TFA), distinct sources of fat are subject to dif-
ferential metabolic processing, which can lead to varying
degrees of hepatic lipid accumulation (Ritze et al. 2013).
Experimental evidence indicates that dietary SFAs and
TFAs negatively impact liver health, while MUFAs and
PUFAs are generally thought to be beneficial. A high
dietary SFA content is associated with NASH in both mice
and humans (Leamy et al. 2013; Toshimitsu et al. 2007). In
mice, the mechanism of liver damage has been shown to
involve hepatocyte apoptosis triggered by oxidative and
ER stress (Leamy et al. 2013). High levels of dietary TFA
also promote NASH in mice through a mechanism
involving enhanced lipogenesis (Machado et al. 2010;
Obara et al. 2010). Although a thorough assessment of the
correlation between TFA consumption and NAFLD in
humans has not been reported, associations with other
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characteristics of the metabolic syndrome have been made
(Micha and Mozaffarian 2009). Dietary supplementation
with MUFAs has been found to decrease liver fat content in
diabetic patients (Bozzetto et al. 2012). The same effect
has been observed in mouse models that develop NAFLD
(Lee et al. 2011; Yang et al. 2011). In the context of a
healthy liver, however, mice fed a diet high in MUFAs
develop hepatic steatosis, although this effect is accom-
panied by a protective decrease in inflammatory signaling
(Ferramosca et al. 2008; Guo et al. 2012). PUFAs, spe-
cifically the n-3 type (omega-3 fatty acids), have the most
beneficial effects on liver health. Mechanistically, they
negatively regulate lipogenesis and inflammatory signaling
while promoting fatty acid breakdown (Di Minno et al.
2012). Depletion of PUFAs from the diet induces fatty liver
in mice (Pachikian et al. 2011), and their supplementation
can prevent or reverse steatosis (Alwayn et al. 2005; Sekiya
et al. 2003). Clinical trials have also demonstrated success
in decreasing hepatic fat content, serum liver enzymes,
hepatocyte damage, and inflammation in NASH patients
treated with a diet high in n-3 PUFAs (Capanni et al. 2006;
Tanaka et al. 2008).
Carbohydrate content is another dietary factor that can
significantly influence the course of disease development in
progressive NAFLD. Ketogenic diets (KD) have a very low
amount of total carbohydrates, and they are typically high
in fat. Mice fed such a diet develop steatosis with faster
kinetics than mice fed a ‘‘Western diet’’ with high levels of
fat and simple carbohydrates (Garbow et al. 2011). KD-fed
mice go on to develop NASH without becoming obese.
Dietary carbohydrates can be broadly classified as either
simple (sugars) or complex (starches), and each has distinct
effects on metabolic syndrome-associated conditions (Aller
et al. 2011). Simple carbohydrates are more easily digested
and absorbed, as complex carbohydrates must be broken
down into their constituent sugars before they can be
processed further. Diets high in simple carbohydrates have
been found to promote steatosis in mice more readily than
matched diets with complex carbohydrates (Isken et al.
2010).
Of the major dietary sugars, fructose has been found to
be a particularly strong driver of NAFLD and NASH
(Basaranoglu et al. 2013; Nomura and Yamanouchi 2012).
One reason for this effect is its efficient uptake and meta-
bolic processing by the liver. Solute carrier family 2,
facilitated glucose transporter member 5 (Slc2a5 or Glut5)
is a membrane transport protein that specifically facilitates
the uptake of dietary fructose from the intestinal lumen into
the portal circulation. Along with family member Slc2a2/
Glut2, which additionally transports glucose and galactose,
Slc2a5 efficiently moves fructose from the bloodstream
into hepatocytes in an insulin-independent manner. In the
liver, fructose is rapidly metabolized by glycolytic and
lipogenic pathways through a mechanism that bypasses a
major rate-limiting step utilized in glucose metabolism.
Mice on a high fructose diet exhibit increased hepatic
expression of lipogenic proteins, elevated serum ALT, and
NASH characterized by mixed micro- and macrovesicular
steatosis after 16 weeks (Schultz et al. 2013). These phe-
notypes develop in the absence of obesity and, at least at
this experimental time point, are not significantly increased
in severity by the addition of a high fat content to the high
fructose diet. Supplementation of other NAFLD models
with a high fructose diet can significantly increase the
severity of developed liver pathologies (Charlton et al.
2011; Dowman et al. 2014; Pickens et al. 2010; Tetri et al.
2008). Excessive fructose intake has also been linked to the
occurrence and severity of NAFLD in humans (Abdel-
malek et al. 2010; Ouyang et al. 2008; Zelber-Sagi et al.
2007). Given the high level of human fructose consump-
tion, mouse models of progressive NAFLD incorporating
this variable are likely to provide valuable mechanistic
insight with high relevance to human disease.
Methionine, choline, and folate are essential nutrients,
which means that they cannot be synthesized de novo by
the body and must be included in the diet. Feeding mice a
methionine- and choline-deficient (MCD) diet leads to
aggressive, early-onset NASH and fibrosis that is mecha-
nistically linked to oxidative stress (Gao et al. 2004; Ri-
nella and Green 2004). Methionine deficiency alone can
cause fibrotic NASH, while choline deficiency cannot,
though it does significantly increase the extent of steatosis
in the context of methionine deficiency (Caballero et al.
2010). Co-deficiency of dietary choline and folate results in
NAFLD that variably progresses to NASH and fibrosis
depending on strain background (Pogribny et al. 2013).
A potential unifying factor underlying these distinct
dietary models is the mechanistic involvement of disrup-
tion in the metabolism of S-adenosylmethionine (SAM),
which has many cellular functions important for liver
health (Lu and Mato 2012). Methionine is the direct met-
abolic precursor to SAM, and its levels are replenished by
metabolic processing of choline and folate. As such, defi-
ciency of these nutrients causes SAM depletion. Restora-
tion of hepatic SAM levels reduces the severity of liver
disease induced by the MCD diet, indicating the impor-
tance of this molecule in the model system (Henkel et al.
2009). SAM serves as the primary methyl donor for a
variety of biological substrates and can be metabolically
processed to generate the critical antioxidant glutathione
(GSH).
Several genetic models have been generated that dem-
onstrate the importance of SAM regulation in maintaining
liver health (Lu and Mato 2012). Constitutive knockout of
methionine adenosyltransferase 1 alpha (Mat1a), which
encodes the enzyme responsible for converting hepatic
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methionine to SAM, results in its depletion and promotes
spontaneous NASH that progresses to HCC (Lu et al. 2001;
Martinez-Chantar et al. 2002). Oxidative stress is high in
this model due to a deficiency of GSH. The relevance of
this model to human disease is demonstrated by studies
identifying hypermethylation of the MAT1A promoter
region and associated decreased expression in the livers of
patients with NAFLD and HCC (Frau et al. 2012; Murphy
et al. 2013). A similar liver phenotype develops in mice with
constitutive knockout of betaine-homocysteine S-methyl-
transferase (Bhmt). Bhmt is an enzyme that generates
methionine by transferring a methyl group from betaine (a
choline derivative) to homocysteine, and hepatic SAM levels
drop by over 40 % in its absence (Teng et al. 2011). Loss-of-
function mutations in BHMT have been detected in human
HCC, suggesting that its absence may contribute to hepato-
carcinogenesis (Pellanda et al. 2012). Steatosis, fibrosis, and
HCC develop spontaneously in mice deficient for glycine N-
methyltransferase (Gnmt), which encodes an enzyme that
catalyzes the transfer of a methyl group to glycine as a way to
regulate cellular SAM levels and prevent aberrant methyla-
tion of other substrates (Martinez-Chantar et al. 2008). In its
absence excessive levels of SAM accumulate in the liver,
leading to excessive methylation of DNA and histones. Data
from human studies similarly suggest that GNMT acts as a
tumor suppressor in the liver. Its expression is frequently
decreased in HCC in association with hypermethylation of
the locus (Chen et al. 1998; Huidobro et al. 2013). Addi-
tionally, MAT1A, BHMT, and GNMT were found to be
coordinately downregulated in human cirrhosis and HCC,
along with other genes involved in SAM metabolism (Avila
et al. 2000). As demonstrated by these mouse models and
their connection to human liver disease, maintenance of
normal SAM levels is critical; either a deficiency or an excess
can cause liver pathologies including NASH, fibrosis, and
HCC.
Insights gained from mouse models of progressive
NAFLD
Mouse models of progressive NAFLD have provided many
valuable insights into the pathogenesis of this prevalent
human disease, increasing our understanding of its envi-
ronmental and molecular drivers. Such knowledge is crit-
ical for the development of improved diagnostic,
prognostic, preventative, and therapeutic approaches. The
generation of model systems through genetic targeting to
manipulate specific signaling pathways has definitively
demonstrated their importance in NAFLD development
and progression, with comparison to human disease veri-
fying their clinical relevance. As reviewed here, the PI3K/
AKT, JAK/STAT, PPAR, and NF-jB pathways have
emerged as central regulators of progressive NAFLD.
However, crosstalk between these and additional signaling
pathways is certain to have a role in the pathogenesis of
this complex disease. Examples include activation of
PPAR-c and mitogen-activated protein kinase (MAPK)
signaling in the liver of mice with genetic PI3K/AKT
pathway activation or JAK/STAT pathway deficiency
(Horie et al. 2004; Mueller et al. 2011; Sos et al. 2011) and
the involvement of upregulated NF-jB and hedgehog (Hh)
signaling pathways in MCD diet-induced NASH (Dela
Pena et al. 2005; Syn et al. 2012). It is becoming
increasingly evident that the ultimate determination of liver
phenotype in NAFLD depends on the integration of several
signals coming from distinct pathways and cell types.
Mouse models have also helped to elucidate key cellular
processes underlying the development of progressive NA-
FLD, including oxidative and ER stress (Malhi and Kauf-
man 2011; Rolo et al. 2012). Activation of the ER stress
response is associated with NAFLD caused by a wide
variety of distinct molecular mechanisms, and it has been
mechanistically linked to both the induction of hepatic
steatosis and its progression to more severe liver damage
(Zhang et al. 2014). The effects on steatosis are mediated
primarily through enhanced lipogenesis, while advance-
ment to NASH is driven by increased apoptosis and oxi-
dative stress-associated inflammation within the liver. The
shared contribution of processes such as oxidative and ER
stress to progressive NAFLD serves to mechanistically
unite seemingly disparate model systems. It also suggests
that therapeutic approaches designed to minimize the
damaging effects of these processes may be especially
efficacious.
The importance of genetic background in determining
the degree of susceptibility to genetically or environmen-
tally induced progressive NAFLD is another key insight
provided by mouse models. Several studies have demon-
strated profound interstrain variability in hepatic pheno-
types induced by liver damaging treatments (Hill-Baskin
et al. 2009; Kahle et al. 2013; Montgomery et al. 2013;
Pogribny et al. 2013; Shockley et al. 2009; Tryndyak et al.
2012; Yamazaki et al. 2008). Similar gene-environment
interactions undoubtedly factor into the pathogenesis of
human NAFLD. Indeed, genetic factors involved in a
diverse array of cellular processes have been identified as
contributors to human NAFLD susceptibility in recent
years (Al-Serri et al. 2012; Carulli et al. 2009; Chalasani
et al. 2010; Gawrieh et al. 2012; Musso et al. 2013; Romeo
et al. 2008; Yoneda et al. 2008).
Knowledge gained through the use of mouse models of
progressive NAFLD has improved our understanding of
this disease in humans. Clarification of the major forces
promoting disease development in a variety of genetic and
environmental contexts has led to the identification of
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promising diagnostic markers and therapeutic targets.
These and future discoveries made using mouse models
will help to alleviate the health burden imposed by the
rising incidence of progressive NAFLD worldwide.
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